Journal of Cancer Policy最新文献

{"title":"Travel patterns of patients seeking cancer care during the COVID-19 pandemic: Multi-centre cohort study in Osaka, Japan","authors":"Mari Kajiwara Saito,&nbsp;Toshitaka Morishima,&nbsp;Chaochen Ma,&nbsp;Shihoko Koyama,&nbsp;Isao Miyashiro","doi":"10.1016/j.jcpo.2023.100416","DOIUrl":"10.1016/j.jcpo.2023.100416","url":null,"abstract":"<div><h3>Background</h3><p>In Japan, provision of equal access to cancer care is intended to be achieved via secondary medical areas (SMAs). However, the percentage of patients receiving care within the residential area varies by SMA in Osaka Prefecture. We aimed to assess the effect size of factors associated with patient mobility, and whether patient mobility was affected by the COVID-19 pandemic.</p></div><div><h3>Methods</h3><p>Records of patients diagnosed with stomach, colorectal, lung, breast, cervical, oesophageal, liver or pancreatic cancer during 2019–2020 were extracted from multi-centre hospital-based cancer registry data. Odds ratios of whether a patient received care within the SMA of residence were set as the outcome. A multivariable model was built using generalised estimating equations with multiple imputation for missing data. Change in patient mobility after the pandemic was examined by deriving age- and SMA-specific adjusted ORs (aORs).</p></div><div><h3>Results</h3><p>A total of 78,839 records were included. Older age, more advanced stage and palliative care had up to 1.69 times higher aORs of receiving care within their own area. Patients with oesophageal, liver or pancreatic cancer tended to travel outside their area with aORs ranging from 0.71 to 0.90. Patients aged ≤ 79 and living in the East and South SMAs tended to remain in their area with aORs ranging from 1.05 to 1.11 after the pandemic.</p></div><div><h3>Conclusion</h3><p>Patient mobility decreased for higher age and stage. It also varied by SMA, cancer site and treatment type.</p></div><div><h3>Policy Summary</h3><p>Our results need to be linked with resource inputs to help policymakers decide whether to intervene to address current efficiency or equity issues.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9951607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9615450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world outcomes associated with use of front-line bevacizumab in ovarian cancer","authors":"Josee-Lyne Ethier ,&nbsp;Weidong Kong ,&nbsp;Helen J. MacKay ,&nbsp;Jacob McGee ,&nbsp;Christopher M. Booth","doi":"10.1016/j.jcpo.2023.100421","DOIUrl":"10.1016/j.jcpo.2023.100421","url":null,"abstract":"<div><h3>Background</h3><p>In the pivotal ICON7 study, addition of bevacizumab to front-line treatment of ovarian cancer (OC) significantly improved overall survival (OS) (p = 0.03) in a high-risk subgroup of patients with suboptimally debulked/unresectable stage III or IV disease, leading to approval in Ontario, Canada in March 2016. Here we describe utilization of bevacizumab for front-line, high-risk OC and determine outcomes in routine clinical practice.</p></div><div><h3>Methods</h3><p>Provincial administrative databases were utilized to identify all patients treated with front-line bevacizumab following its approval. Median OS (mOS) was determined using the Kaplan-Meier method. Factors associated with OS were identified using a Cox proportional hazard model. A comparative effectiveness analysis was performed to determine mOS pre- (2006–2016) and post- (2016–2019) approval.</p></div><div><h3>Results</h3><p>From March 2016 to October 2019, 282 patients received bevacizumab. Mean age was 64 years old, and 58% had stage IV disease. Median survival was 29 months and was longer in stage III (37 months) compared to stage IV disease (28 months). In a comparative effectiveness analysis of patients with stage IV serous OC, post-approval uptake of bevacizumab was low (23%). Median OS was similar pre (26 months) and post (27 months) approval (HR 0.92, 0.75–1.12, p = 0.383).</p></div><div><h3>Conclusions</h3><p>Survival in real-world patients treated with front-line bevacizumab is shorter than in pivotal clinical trials. Survival in stage IV serous patients has not significantly improved post public reimbursement of bevacizumab. This analysis was limited by poor uptake, however mOS was similar in patients who did and did not receive bevacizumab.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9616375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five changes needed to Scottish cancer policy to support necessary transformation of services","authors":"Ashleigh L. Ward ,&nbsp;Liz Forbat","doi":"10.1016/j.jcpo.2023.100420","DOIUrl":"10.1016/j.jcpo.2023.100420","url":null,"abstract":"<div><p>Whilst Scottish healthcare policy has not yet set a clear direction for service transformation needed in lieu of budgetary constraints, it is important that policy makers are cognisant of where policy can support healthcare professionals to overcome barriers to service development, and better meet demand. An analysis of Scottish cancer policy is presented, informed by learning gained from supporting development of cancer services as a practitioner, insights from undertaking health service research, and known barriers to service developments. This paper is structured as five recommendations to policy-makers: the need to develop a shared understanding of quality care between policy makers and healthcare professionals to guide service development in the same direction; revisiting of partnership working given developing health and social care landscape; empowerment of national and regional networks and working groups to develop and implement Gold Standard care in speciality services; sustainability in the development of cancer services; and development of guidance relating to how services should be using and developing patient capacities.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9972080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors affecting cervical cancer screening service uptake among clients visiting the ART clinic at Hawassa University Comprehensive Specialized Hospital, Hawassa, Ethiopia: A cross-sectional study","authors":"Birhanu Lulu ,&nbsp;Eskindir Loha ,&nbsp;Asnakech Agegnehu","doi":"10.1016/j.jcpo.2023.100422","DOIUrl":"10.1016/j.jcpo.2023.100422","url":null,"abstract":"<div><h3>Background</h3><p>Annually, around half a million new cases of cervical cancer and 250,000 deaths occur worldwide. It is the second-leading cancerous cause of death after breast cancer among women. Repeated infection and prolonged persistence with human papilloma virus is common among HIV-positive women due to their immune status. A one-visit screen and treat strategy for cervical cancer prevention was instituted in 2010 nationwide in 14 selected hospitals. So, assessing service uptake and associated factors among ART clients is mandatory.</p></div><div><h3>Method</h3><p>From December 2015 to March 2016 G.C., a cross-sectional study was conducted<strong>.</strong> An interviewer-administered, semi-structured questionnaire was used to collect data. The data were entered, cleaned, and analyzed using IBM SPSS version 20 software. A statistically significant association of variables was determined based on an adjusted odds ratio with a 95 % confidence interval and a p value of 0.05.</p></div><div><h3>Result</h3><p><strong>C</strong>ervical cancer screening service uptake among the 647 interviewed participants was 59 %. Study participants accounting for 19 % (N = 123) were 18–29 age group, 56.6 % (N = 366) were 30–39 %, and 24.4 % (N = 158) were in 40–64 age group. Of 647 participants, 43.7 % (N = 283) were illiterate and educated less than secondary level of education, 36.0 % (N = 233) had a secondary level of education, and 20.2 % (N = 131) had an education above secondary. Being encouraged by others to get screened for cervical cancer (AOR = 1.88, 95 % CI: 1.25, 2.82), knowing another woman who got screened, and getting information from the media (AOR = 0.4, 95 % CI: 0.27, 0.60) were associated with the uptake of cervical cancer screening.</p></div><div><h3>Conclusion</h3><p>The uptake of cervical cancer screening among ART clients attending the clinic was not satisfactory. Encouragement to get screened, knowing other screened women, and getting information from the media were important predictors of CCS service uptake. Exploring more information on the attitudes of clients to improve service uptake is mandatory.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9616377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of patient advocates and sarcoma community initiatives in musculoskeletal oncology. Moving towards Evidence-Based Advocacy to empower Evidence-Based Medicine","authors":"Ornella Gonzato ,&nbsp;Kathrin Schuster","doi":"10.1016/j.jcpo.2023.100413","DOIUrl":"10.1016/j.jcpo.2023.100413","url":null,"abstract":"<div><p>Musculoskeletal sarcomas are rare cancers that as the whole family of sarcomas pose several challenges at different levels, ranging from medical knowledge to clinical research and policymaking. Addressing these challenges, necessarily calls for the inclusion of patient perspective inside the decision-making processes of every area that contributes to treatment improvement, from the provision of high-quality services by healthcare organisations to research issues. Without patient-provided inputs to inform decisions, the current paradigm of patient-centred care makes no sense and sounds at the least irrational if not unethical. Putting PROMs on “centre stage” in cancer research and care, could allow to build a truly Evidence Based Advocacy (EBA) and therefore to empower Evidence Based Medicine (EBM).</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9616693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy activity in the COVID 19 pandemic: Brazil's operational national-level study","authors":"Fabio Y. Moraes ,&nbsp;Andre G. Gouveia ,&nbsp;Renato P. Lima ,&nbsp;Vanessa F. Bratti ,&nbsp;Ana C. Hamamura ,&nbsp;Gustavo A. Viani","doi":"10.1016/j.jcpo.2022.100367","DOIUrl":"10.1016/j.jcpo.2022.100367","url":null,"abstract":"<div><h3>Purpose</h3><p>During the COVID-19 pandemic, patients with cancer are at increased risk of not having timely diagnosis and access to cancer treatment. The present study evaluated the COVID-19 pandemic impact on radiotherapy activity in Brazil.</p></div><div><h3>Methods</h3><p>A national-level study was performed to evaluate the RT utilization for prostate, breast, head &amp; neck (HN), Gynecology (GYN), Gastrointestinal (GI), lung cancers, and bone/brain metastases. The data on the RT executed was extracted from the Brazilian Ministry of Health database. The NON-COVID period was considered the control group, and the comparison groups were COVID-2020 (without vaccine) and COVID-2021 (with vaccine).</p></div><div><h3>Results</h3><p>We collected the data of 238,355 procedures executed on three periods. Significant difference in the RT utilization between NON-COVID and COVID-2020 were observed for prostate cancer, bone and brain metastases (−12.3 %, p = 0.02, +24 %, p = 0.02 and +14 %, p = 0.04, respectively). Comparing 2 equivalents months from NON-COVID-2019 (ref), COVID-2020, and COVID-2021, a significant increase was identified for bone and brain metastases (2020 +21 %, and 2021 +32 %), and (2020 +20 %, and 2021 +14 %). A stable drop occurred for prostate cancer (2020 −11 % and 2021 −10 %), and a variation was observed for breast (2020 +8 %, and 2021 −1 %) and lung cancer (2020 +10 %, and 2021 −3 %). For other cancers, non-significant changes were observed when comparing 2020 and 2021.</p></div><div><h3>Conclusion</h3><p>The RT activity was heterogeneously affected with a substantial increase for bone and brain metastases and a meaningful decline for prostate cancer.</p></div><div><h3>Policy summary</h3><p>With a significant increase in the use of palliative radiotherapy for bone and brain metastases and a meaningful reduction in curative radiotherapy for prostate cancer, we hope these findings can help governments, RT services, medical communities, and other stakeholders develop strategies to mitigate the impact of the present and future pandemics. Finally, despite the changes imposed by the COVID pandemic, it is imperative to enhance screening, increase cancer diagnosis at an early stage, and improve access to all cancer treatments, including radiotherapy.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540705/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9988231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decolonising medical knowledge – The case of breast cancer and ethnicity in the UK","authors":"Sarah Catherine Workman ,&nbsp;Maddy C. Thompson ,&nbsp;Lisa Lau","doi":"10.1016/j.jcpo.2022.100365","DOIUrl":"10.1016/j.jcpo.2022.100365","url":null,"abstract":"<div><p>National and global efforts have led to significant improvements in breast health and diagnosis, globally (Lukong, 2017). These achievements, however, are not even. Focusing on the case of breast cancer in the UK, we argue that enduring forms of medical racism leave Black women more vulnerable to advanced forms of the disease, explaining higher mortality rates and later-stage diagnosis. In particular, we show how a lack of dedicated policy, inadequate data collection, and a lack of representation conspire to place Black women at additional and unnecessary risk of worse breast cancer outcomes. We thus propose key recommendations to address the ethnic disparities in and make steps to decolonise breast cancer care. These are early screening for at-risk groups, community-led interventions, and more and better representation of Black women and their risks in breast cancer resources.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9970582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Peer reviewers from low- and middle-income countries(LMIC) for open access journals in oncology can improve the equity in cancer research and clinical trials","authors":"Bidhu Kalyan Mohanti ,&nbsp;Anusheel Munshi ,&nbsp;Biplab Sarkar ,&nbsp;Atul Sharma ,&nbsp;Surya VS Deo","doi":"10.1016/j.jcpo.2023.100419","DOIUrl":"10.1016/j.jcpo.2023.100419","url":null,"abstract":"<div><p>Open access journals (OAJ) in biomedicine are promoted to improve the reach and distribution of global health research (GHR). However, in the last 20 years, article publishing charge (APC) is attracting and publishing the vast majority of papers from high-income countries (HIC) in “oncology” journals under OAJ. This paper outlines the impediments for cancer research and publication from low-and middle-income countries (LMIC): (a) existing disparities in cancer care facilities and survival outcomes between HIC and LMIC, (b) more than 70 % of OAJ in 'oncology' subject levy APC, becoming unaffordable for scientists and clinicians from LMIC, (c) impactful OAJ in oncology engage less than 10 % of members from LMIC in editorial board or as peer reviewer, whereas two-third of cancer diagnosis and management occur in these countries. Peer review serves the editors by recommending the relevant papers. Thus, peer reviewers from developing countries working for the OAJs in “oncology” can increase the diversity in publication, improving the GHR in cancer management. The cancer research and clinical trials which can bring to notice the challenges and hurdles faced by researchers, clinicians and cancer patients in LMIC will be served to some measure by engaging peer reviewers from those countries who understand the ecosystem.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9608130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating stigma during the COVID-19 pandemic: Living conditions, social determinants and experiences of infection among employees at a tertiary referral cancer centre","authors":"Priya Ranganathan ,&nbsp;Sandeep Tandon ,&nbsp;Sufiyan Khan ,&nbsp;Pooja Sharma ,&nbsp;Sanjeev Sharma ,&nbsp;Gauravi Mishra ,&nbsp;Bindhulakshmi Pattadath ,&nbsp;Sindhu Nair ,&nbsp;Pankaj Rajput ,&nbsp;Carlo Caduff","doi":"10.1016/j.jcpo.2023.100412","DOIUrl":"10.1016/j.jcpo.2023.100412","url":null,"abstract":"<div><h3>Aim</h3><p>Healthcare workers (HCWs) have reported negative social experiences during the COVID-19 pandemic; however, this data is largely from medical personnel. We examined living conditions, social determinants, and experiences during the COVID-19 pandemic among all cadres of employees who had recovered from COVID-19 at a tertiary referral cancer hospital in India.</p></div><div><h3>Methods</h3><p>We conducted a mixed methods study combining a questionnaire-based survey followed by semi-structured interviews with open-ended questions, among hospital staff who recovered from COVID-19 between April and November 2020. We initially administered a 79-point survey to all participants; based on their responses, we used purposive sampling to identify 60 interview participants. The primary aim of the study was to examine the impact of socio-economic factors on experiences and potential stigma faced by staff during the COVID-19 pandemic.</p></div><div><h3>Results</h3><p>We surveyed 376 participants including doctors (10 %), nurses (20 %), support staff (29 %), administrators (18 %) and scientists/technicians (22 %). Of these, 126 (34 %) participants reported negative social experiences. Stigmatisation was lower among doctors compared to other professions, decreased in the second half of the study period, and was more among those living in less affluent surroundings. Interviews revealed 3 types of negative social experiences: neighbourhood tensions around restrictions of mobility, social distancing, and harassment.</p></div><div><h3>Conclusions</h3><p>The first phase of the COVID-19 pandemic in India led to considerable negative social experiences among hospital employees, especially those lower in the socio-economic hierarchy, which was fuelled by restrictions imposed by the government and pressure on local neighbourhoods.</p></div><div><h3>Policy summary</h3><p>It is important to not just document and count stigma experiences during global pandemics, but also to examine sociologically the conditions under which and the processes through which stigma happens.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9930404/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9616692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of preparedness, timing of cancer diagnosis, and objective emergency preparedness among gynecological cancer patients in Puerto Rico before and after Hurricane Maria","authors":"Meghan Johnson ,&nbsp;Humberto Parada Jr ,&nbsp;Karen Ferran ,&nbsp;Ramona Perez ,&nbsp;William Calo ,&nbsp;Istoni da Luz Sant'Ana ,&nbsp;Liz Martínez Ocasio ,&nbsp;Pablo A. Mendez-Lazaro ,&nbsp;Sandra I. Garcia ,&nbsp;Guillermo Tortolero-Luna ,&nbsp;Sharee A. Umpierre ,&nbsp;Ana Patricia Ortiz","doi":"10.1016/j.jcpo.2023.100415","DOIUrl":"10.1016/j.jcpo.2023.100415","url":null,"abstract":"<div><h3>Objectives</h3><p>This study investigated the impact of cancer diagnosis status, individual feelings of preparedness, and other covariates on objective emergency preparedness among women diagnosed with gynecological cancers before or after the 2017 Hurricanes Irma and Maria in Puerto Rico.</p></div><div><h3>Methods</h3><p>This study included 240 women who were interviewed by telephone from 9/2019–11/2020. Objective emergency preparedness was assessed using a list of six items. Subjective emergency preparedness was assessed by asking the women how prepared they felt (well, somewhat, or not at all) to face an emergency. Crude and multivariable logistic regression analyses were conducted to assess the associations (odds ratios [ORs] and 95% confidence intervals [CIs]) between variables of interest and objective preparedness.</p></div><div><h3>Results</h3><p>Before and after the hurricanes, 60% and 66% of women, respectively, were objectively prepared. Before the hurricanes, women reporting feeling well-prepared (vs. not prepared) (OR=9.31, 95%CI:3.96–21.91) and those who were diagnosed before (vs. after) the hurricanes (OR=1.71, 95%CI:0.95–3.09) were more likely to be objectively prepared. After the hurricanes, self-perceived well-preparedness (OR=2.46, 95% CI: 1.10–5.51) was positively associated with emergency preparedness when compared to feeling unprepared.</p></div><div><h3>Conclusions</h3><p>Perceptions of emergency preparedness and having a cancer diagnosis increased the likelihood of being objectively prepared for an emergency.</p></div><div><h3>Policy summary</h3><p>This study demonstrates the need for state, territorial, and federal governments to include emergency preparedness plans for cancer patients in the Comprehensive Cancer Control plans. The study also indicates a need for cancer specific emergency preparedness information to be readily available for patients.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9613969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}